The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Recurrent Neuroblastoma ¹

Added text ² to state that cyclophosphamide plus topotecan has been active in patients with recurrent or refractory disease who have not received topotecan previously.

Added text ² to state that 131-I-MIBG therapy is also active in patients with recurrent or refractory neuroblastoma (cited Matthay et al. as reference 5).